drugset / Trial / NCT06901622
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of camrelizumab and chemotherapy with or without anlotinib as first-line treatment for advanced gallbladder cancer and extrahepatic cholangiocarcinoma
Timeline
- Start
- 2024-11-08
- Primary completion
- 2026-03-01
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Nab-paclitaxel | Small molecule | 200 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 60 mg | — |
| Subject | S-1 | Small molecule | 80 mg | — |
| Subject | S-1 | Small molecule | 100 mg | — |